Fibromyalgia is one of the most common chronic pain conditions, affecting an estimated 2–4% of the general population — predominantly, though not exclusively, women. Despite its prevalence, it remains poorly understood by many clinicians and is frequently dismissed or under-treated. For those living with it, the reality is an often-invisible, deeply debilitating condition that affects every aspect of daily life.
This article presents what is currently understood about fibromyalgia management — honestly, without overpromising on behalf of any single approach.
Fibromyalgia is characterised by widespread musculoskeletal pain, fatigue, sleep disturbances, and often cognitive symptoms ('fibro fog'). The current understanding positions it as a condition of central sensitisation — a state in which the central nervous system becomes hyperresponsive to pain signals, amplifying them beyond their normal intensity.
Diagnosis is clinical, based on the 2016 ACR diagnostic criteria. There is no blood test or imaging finding that definitively confirms fibromyalgia. Diagnosis requires the exclusion of other conditions that could account for the symptoms — rheumatoid arthritis, lupus, thyroid disease, and others — making a thorough medical workup important.
Pharmacological options for fibromyalgia have modest evidence at best. Duloxetine (an SNRI antidepressant), pregabalin, and milnacipran are the medications with the strongest evidence base and regulatory approval for fibromyalgia in various countries. They can meaningfully reduce pain in some patients but do not work for everyone and carry side effect profiles that limit their use in others.
Simple analgesics, including paracetamol and NSAIDs, have limited evidence for fibromyalgia pain. Opioids are generally not recommended and may worsen central sensitisation over time.
Low-to-moderate intensity aerobic exercise is the most consistently evidence-supported treatment for fibromyalgia. Multiple systematic reviews confirm its benefits for pain, fatigue, and overall function. The challenge is that exercise intolerance is common in fibromyalgia — starting very gradually and increasing extremely slowly is essential to avoid flares.
CBT for chronic pain has good evidence for reducing pain catastrophising, improving function, and enhancing quality of life, even when it does not reduce pain intensity itself. It addresses the psychological amplification of pain that central sensitisation creates.
MBSR has growing evidence for fibromyalgia. Its mechanism — reducing the stress and emotional reactivity that amplify pain signals — is well-matched to the central sensitisation model of fibromyalgia.
Warm water exercise is particularly well-tolerated in fibromyalgia. The warmth reduces muscle tension and pain, and buoyancy reduces joint loading. Aquatic physiotherapy is a practical first exercise option for many patients.
Electrostimulation — both TENS and microcurrent — has been used in chronic pain management contexts, including fibromyalgia. The rationale is that electrical stimulation may modulate pain signal processing and support localised pain relief in affected areas.
Microcurrent electrotherapy works at the cellular level with very low-intensity currents. The KFH Energy is FDA-cleared for pain relief (510(k) K073008) and may be used by fibromyalgia patients as a drug-free adjunct for managing localised areas of pain. It is portable, can be used at home, and does not require exertion — an important advantage for patients in whom activity is limited.
KFH Energy is a pain relief device. It does not treat fibromyalgia itself, does not address central sensitisation, and is not a cure for any aspect of the condition. It may help some patients manage localised pain as part of a broader, multidisciplinary approach.
Fibromyalgia management is typically most effective as a multidisciplinary programme: pain medicine, physiotherapy, psychology, and self-management education working together. Pace management — learning to avoid the overactivity-crash cycle — is as important as any specific treatment.
Patient communities and support groups — nationally recognised fibromyalgia associations exist in most countries — provide invaluable practical support, advocacy, and the lived experience that clinical guidelines cannot fully capture.
DISCLAIMER: Fibromyalgia requires specialist diagnosis and management. This article is for informational purposes only. Consult a rheumatologist or pain specialist. KFH Energy is an FDA-cleared pain relief device (510(k) K073008) and is not a treatment for fibromyalgia. Individual results may vary.
